What is the purpose of this trial?
The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.
Ages: 18 - 70 years
Nancy Taylor Foundation for Chronic Diseases, Inc.
Start Date: 03/19/2016
End Date: 03/15/2022
Last Updated: 05/15/2018
Study HIC#: 1511016789